Anticancer vaccines have gained a new lease of life with techniques to personalise them to individual patients. Cutting edge developments in this re-energised field were revealed at the ESMO Immuno-Oncology Congress in Geneva, Switzerland.
The original anticancer vaccines, launched in the late 1990s, were based on shared tumour antigens and failed to induce a potent immune response. After decades of disappointing results, a number of advances have sparked a renewed interest in the field. These include new technologies and prediction algorithms to personalise vaccines, and the introduction of check point inhibitors for combination therapy
Dr Michal Bassani-Sternberg, Group Leader, Immunopeptidomics, Hi-TIDe Laboratory, Department of Oncology, University of Lausanne, Switzerland, and the Ludwig Institute for Cancer Research in Lausanne, said: “The ‘Modern anticancer vaccines’ session at the ESMO Immuno-Oncology Congress was timely since there is again a flurry of activity around anticancer vaccines. We can now customise vaccines for each patient based on the genomic information in their tumour, and the early results are promising.”
Personalisation has been made possible with high-throughput next generation sequencing. This technology identifies mutations that are unique to a patient’s tumour and are not found elsewhere in the body, meaning that a vaccine mounts a local immune response. Algorithms can predict which neoantigens should be targeted for vaccination.
Bassani-Sternberg said: “We have a good way to fish out and propose targets for vaccination. The first trials were published last year and showed that the selected targets were immunogenic, meaning that vaccination induced immune responses or amplified existing immune responses against these neoantigens. In addition, the vaccines worked well with check point inhibitors. We now need to see if vaccination against neoantigens leads to tumour regression.”
Neoantigens were explored in a dedicated session at the ESMO Immuno-Oncology Congress and were discussed in the session on modern anticancer vaccines, which also described the role of other vaccine targets. These include oncogenic proteins such as HER2, pathogens like the human papilloma virus (HPV), and prostate-specific antigens. These shared antigens are also being tested in combination with check point inhibitors.
Bassani-Sternberg said the combination of modern anticancer vaccines and check point inhibitors appears to generate the most effective immune response. “Vaccines can induce new responses in patients with ‘cold tumours’ which lack immune cells, thus making the environment receptive to check point inhibitors,” she said.
Numerous questions remain unanswered, such as when to vaccinate patients. Should this be immediately after surgery, when there are few tumour cells left, or beforehand? Should vaccines be administered against primary tumours and metastases? Will it be necessary to give new vaccines every few months as tumours evolve naturally and in response to treatment? How and when should vaccines be combined with other therapies?
But despite these questions, vaccination appears feasible. The technology to develop vaccines is available and getting better, the vaccines are safe and immunogenic, and there is openness from the regulators to testing vaccines in clinical trials. Bassani-Sternberg said: “We are counting on new technologies that have now matured. Next generation sequencing has made identification of vaccine targets more efficient, reliable, and cheaper. The algorithms to interpret this data are benchmarked and validated for predicting which targets are most likely to be immunogenic. Sequencing technologies are only going to get better and prediction tools will become even more accurate.”
“There is great hope for vaccines,” she continued. “And they have the potential to benefit most patients because almost all tumours have targets that could be vaccinated.”
Learn more: Anticancer Vaccines Gain new Lease of Life with Personalisation Techniques
The Latest on: Personalized anticancer vaccines
[google_news title=”” keyword=”Personalized anticancer vaccines” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Personalized anticancer vaccines
- Adding immune-boosting agent to personalized cancer vaccine supercharges the body's immune defense against malignant brain tumorson May 9, 2024 at 9:18 am
Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have pinpointed a combination immunotherapy treatment that enhances the immune response for people with malignant gliomas, an ...
- We are closer than ever to having a skin cancer vaccineon May 8, 2024 at 12:14 am
However, in this case, the vaccine is personalized and adapted to each patient's individual needs. A tumor sample is collected. Then, the DNA is sequenced, and with the help of artificial intelligence ...
- New mRNA cancer vaccine helps immune system fight deadly brain tumorson May 7, 2024 at 8:23 am
Researchers from the University of Florida have developed a new mRNA cancer vaccine to retrain the body's immune system to attack and potentially treat glioblastoma, a deadly form of brain cancer.
- Glioblastoma vaccine turns brain tumors from cold to hot in humans and dogson May 7, 2024 at 2:29 am
A personalized mRNA-based cancer vaccine for glioblastoma with an “onion-like” delivery mechanism can prolong survival both in dogs and humans, the results of a small study have suggested.
- Personalized mRNA vaccines: A new approach in melanoma treatmenton May 4, 2024 at 7:50 am
A personalized mRNA vaccine to treat melanoma has now reached late-stage trials in the UK. This is just the latest step in improving the cure rate of cancer.
- MIT Technology Reviewon May 2, 2024 at 5:00 pm
Last week, Moderna and Merck launched a large clinical trial in the UK of a promising new cancer therapy: a personalized vaccine that targets a specific set of mutations found in each individual ...
- MRNA vaccine effective in treating glioblastoma brain cancer in small trialon May 2, 2024 at 9:24 am
An experimental cancer vaccine can quickly reprogram a person's immune system to attack glioblastoma, the most aggressive and lethal form of brain cancer, a small, preliminary study has found.
- Novel mRNA Vaccine Shows Promise Against Deadly Brain Canceron May 1, 2024 at 1:24 pm
Researchers introduced a new mRNA cancer vaccine that rapidly activates the immune system against glioblastoma, the deadliest form of brain tumor.
- British Man Tests First Personalized Melanoma Vaccineon April 30, 2024 at 9:34 am
What sets this vaccine apart is its personalized nature. Tailored to match the genetic signature of each patient's tumor, the vaccine instructs the body to produce proteins or antibodies targeting ...
- Personalized Melanoma Vaccine Could Be a ‘Game Changer’ by Teaching the Body to Fight Cancer Cellson April 29, 2024 at 1:28 pm
The mRNA therapy, designed to prevent treated skin cancer from returning, is entering its third phase of trials ...
via Bing News